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Invasive bladder cancers have been treated by irradiation combined with cis-platinum (CDDP) as a bladder preservative option. The
aim of this study was to find a marker for predicting patient outcome as well as clinical response after chemoradiation therapy (CRT)
by investigating allelic loss of apoptosis-related genes. A total of 67 transitional cell carcinomas of the bladder treated by CRT (median
dose: 32.4Gy of radiation and 232mg of CDDP) were studied. We investigated allelic imbalances at 14 loci on chromosomes 17p13
and 1p36 including the p53 and p73 gene regions by fluorescent multiplex PCR based on DNA from paraffin-embedded tumour
specimens and peripheral blood. The response to CRT was clinical response (CR) in 21 patients (31%), partial response (PR) in 31
(46%), and no change(NC) in 15 (22%). There was no statistical correlation between treatment response and clinical parameters,
such as tumour grade, stage, radiation dose, or CDDP dose. The frequencies of allelic imbalance for TP53 and TP73 were 21 and
56%, respectively; neither was correlated with clinical treatment response and tumour stage or grade. There was no statistical
correlation between treatment response and allelic imbalance at the other 12 loci. We found a significant correlation between
cancer-specific survival and an imbalance of D1S243 (P¼0.0482) or TP73 (P¼0.0013) using a Log-rank test, although other loci
including TP53 did not correlate with survival (P¼0.4529 Multivariate analysis showed performance status (P¼0.0047), recurrence
(P¼0.0017), and radiation doses (P¼0.0468) were independent predictive factors for cancer-specific survival. However, an allelic
imbalance of TP73 was the most remarkable independent predictive factor of poor patient survival (P¼0.0002, risk ratio: 3382). Our
results suggest that the allelic loss of the p73 gene predicts a clinical outcome of locally advanced bladder cancer when treated by
CRT.
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Initial treatments for invasive bladder cancer can be divided into
bladder-sparing therapy and radical cystectomy. Although radical
cystectomy remains the standard treatment, a variety of adjuvant
therapies have been attempted to induce tumour downstaging and
to improve survival. During the last three decades, the most
commonly used bladder-sparing treatment has been external beam
radiation therapy (Shipley et al, 1987). Studies of systemic
chemotherapy combined with radiation prior to surgery have
shown that it can allow bladder preservation by transurethral
resection (TUR) or partial cystectomy in 52–70% of patients with
invasive bladder cancer (Tester et al, 1993; Tester et al, 1996;
Kachnic et al, 1997; Shipley et al, 1997; Shipley et al, 1998). We
have treated locally advanced bladder cancer by a modified version
of Shipley’s regimen using radiation combined with cis-platinum
(CDDP) (Shipley et al,1987). Although many tumours show a good
response to this treatment, several are resistant. Since this therapy
can be unnecessarily harmful for patients whose tumours do not
respond, if we could predict the response of a bladder cancer to
this treatment, it would help choose appropriate candidates for
this therapy regime.
Dysfunction of the p53 tumour suppressor gene located at
17p13.1 is the most frequent alteration in human malignancy and
frequent loss of heterozygosity (LOH) on 17p13.3, distal to p53, has
been reported in breast, colon, ovary, and lung cancers (Tsuchiya
et al, 2000). Mutant P53 protein overexpression is frequently
observed in bladder cancers that show more malignant behaviour.
Loss of p53 function is one of the most important roles in
resistance to chemotherapy or radiation-induced apoptosis. The
incidence of LOH of chromosome 17p or mutation of p53 is 60% or
more in advanced bladder cancer (Sidransky et al, 1991). However,
more than a few patients with bladder cancer harbour p53
alterations and do respond to CDDP. This finding suggests that
there are some pathways other than p53 activation that mediate
CDDP-induced cell death, and that damage to these pathways leads
to clinical crisis.
The p73 gene that has been mapped to chromosome 1p36.3,
which has a high homology to the p53 gene, is also a key factor in
the apoptotic pathway. It has been reported that p73 is a
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lcomponent of a mismatch repair-dependent pathway, and that p73
levels are increased after DNA damage (Agami et al, 1999; Gong
et al, 1999; Yuan et al, 1999). Many studies have suggested that
there may be several tumour suppressor genes on 1p36, such as in
neuroblastoma and hepatocellular carcinoma (Ichimiya et al, 1999;
Fang et al, 2000).
This evidence prompted us to investigate specific loci encom-
passing p53 and p73 genes by microsatellite analysis using the
fluorescent multiplex PCR technique, and to investigate genetic
markers that could help predict the clinical outcome of
chemoradiotherapy in bladder cancer.
MATERIALS AND METHODS
Patients
A cohort of 67 patients, who underwent preoperative chemo-
radiotherapy (CRT) for locally invasive (T2-4N0M0) or high-risk
superficial (pT1G3) bladder cancer between November 1994 and
August 2000, was studied (Table 1). Before treatment, we
performed cold cup biopsies on tumours and selected-site bladder
mucosa that were taken from trigone, both lateral walls, retro-
trigone, dome, anterior wall, bladder neck, and prostatic urethra in
men. Systemic work-up for tumour staging on CT scanning,
intravenous pyelography, and bone scintigram were performed for
all patients. Tumours were graded histopathologically according to
the WHO classification and were staged by the TNM staging
system of the UICC (1992). All patients received preoperative
chemotherapy with cis-diamino-dichloro-platinum (CDDP) intra-
venously plus radiotherapy. The regimen (based on Shipley’s
method) was CDDP (70mgm
 2) on day 1, with radiation
administered by Liniac to the true pelvis at 1.8 grays (Gy) per
fraction from day 2 to day 6 in the first week, and 5 consecutive
days per week thereafter. The therapy was carried out one to three
times every 14 days. The mean total dose was 40.5Gy, ranging
from 30 to 61.2. At the completion of one cycle of CRT,
patients were treated by CDDP of 70mgm
 2 and irradiation of
16.2Gy to the basic target. Although we tried to perform
three cycles of CRT when possible, in those patients who received
one or two cycles of the therapy and who had persistent side
effects such as nausea, vomiting, diarrhoea, and pancytopenia
for 2 weeks or who refused to continue with CRT, the treatment
was halted. At 4 weeks after the completion of CRT, patients
were assessed for response by selected-site mucosal cold
cup biopsy or TUR and CT scanning. The clinical response
to CRT was classified as follows: CR (clinical response),
pathologically no tumour residual in the bladder (pCR) and no
evidence of nodal or visceral metastasis; PR (partial response),
downsizing of the tumour with a decrease of over 50% compared
to the initial tumour, with no evidence of distant or nodal
spread on CT scanning. Cases that were pathologically not pCR
were classified as PR even if the tumour showed complete
disappearance radiographically. NC (no change): persistent
invasive disease that was not downsized by CRT, with or without
evidence of nodal or distant spread. Patients whose tumour
showed NC or whose residual tumour cells remained in the muscle
layer were referred for radical or partial cystectomy with lymph
node dissection, while patients with responding tumours (CR or
PR) underwent complete resection of the cancer by TUR. Six
patients who had just residual carcinoma in situ (CIS) were
subsequently treated by intravesical instillation of Mitomycin C
(MMC) or BCG. Treatment-related toxicities were evaluated by
WHO criteria. Cystoscopic examination followed by washing
cytology was carried out every 3 months from the third to fifth
year and every 6 months thereafter. Complementary examinations,
including chest X-rays and/or CT scans, were carried out every 6
months.
Specimens and DNA extraction
Specimens of tumours collected at the time of initial diagnosis
were studied for the source of tumour DNA. Formalin-fixed
paraffin-embedded tissues were cut into 5-mm sections, and the
first and last sections were used for histopathological analysis with
HE stain. Specimens containing at least more than 75% tumour
cells were used for analysis. Specimens from three-step sections
were used for DNA extraction using DEXPAT (Takara, Tokyo,
Japan) according to the manufacturer’s instructions.
Blood collection
Blood samples from each patient were collected as a normal
control. Blood was treated with EDTA, and lymphocyte DNA was
isolated using a GenTLE extraction kit (Takara, Tokyo, Japan).
PCR amplification
Totally, 14 microsatellite markers containing loci on chromosome
17p13 and 1p36, with two- or three-base pair repeat motifs were
investigated. The primer sequences for these markers were
obtained from the Genome Database (http://gdbwww.gdb.org).
The location of each marker is shown in Table 2. Polymerase chain
reaction (PCR) was carried out in a reaction volume of 10ml
containing 0.2mM of each primer (one of the primers was labelled
with FAM, HEX, or TET), 2mM MgCl2, 0.2mM dNTP, 1U of Taq
polymerase, and approximately 5ng of genomic DNA. Amplifica-
tion was carried out by 40 PCR cycles of 941C for 45s, 551C for
60s, and 721C for 45s.
Multiplex PCR
The multiplex PCR method was the same as described above, with
the exception that 2–5 primer pairs were added in the same PCR
tube. Primers were selected on the basis that the resultant PCR
products could be distinguished by colour and size without
overlapping.
Polyacrylamide gel electrophoresis
The PCR products were subjected to electrophoresis on 4%
polyacrylamide denaturing gel in TBE buffer and analysed using an
Table 1 Patient characteristics
Characteristics No. %
All patients 67
Sex
Male 51 76
Female 16 24
Age (years)
Median 68
Range 45–89
Histopathology
Transitional cell carcinoma 67 100
Pathological grade 15 22
G2 52 78
G3
Clinical stage
T1&G3 12 18
T2 22 33
T3 28 42
T4 5 7
Lymph node metastasis
N(+) 0 0
N( ) 67 100
Median follow-up period (months) 32.6
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Biosystems, CA, USA). In total, 1ml of each PCR product
was resuspended using 3.5ml of loading solution (2.5ml forma-
mide, 0.5mlo f5 0 m M EDTA with 50mgml
 1 Blue Dextran, and
0.5ml of Gene Scan Size Standard: GS500). This mixture was
denatured at 951C for 5min and a 1.5ml aliquot of the mixture was
used for analysis. Electrophoresis was performed for 2h at 40W
and 521C.
Data analysis and calculation of allele ratios
To detect allelic imbalance, the peak area of the two alleles was
calculated by Gene Scan Analysis Software for each tumour
specimen and the corresponding lymphocyte DNA. Allelic
imbalance was defined as a decrease of the signal of one allele
by more than 50% in tumour DNA when compared with
lymphocyte DNA.
Statistical analysis
Correlations of frequency of allelic imbalance with tumour grade,
stage, and response to CRT were assessed using w
2 or Fisher’s exact
tests. Survival after CRT was analysed using the Kaplan–Meier
method with a Log-rank test as univariate analysis. Multivariate
analysis was performed by using Cox’s proportional hazard
regression test in step-wise mode. Data were processed using
JMP 4.0 statistical software, with Po0.05 indicating statistical
significance.
Ethical considerations
Our research was carried out in accordance with the principles set
out in the Declaration of Helsinki 1964 and all subsequent
revisions, informed consent was obtained, and the ethical review
committee of Yamaguchi University School of Medicine approved
the study.
RESULTS
Treatment response and prognosis
A total of 67 patients (median age: 68 years; range: 45–89) received
CRT with a median follow-up period of 32.6 months (range: 2.9–
84.2) and were eligible for evaluation (Table 1). The average total
dose of CDDP and radiation was 230mg (median 220mg, range:
75–375) and 40.5Gy (median 32.4, range: 30–61.2), respectively.
Treatment-related toxicity such as anemia, leucocytopenia,
thrombocytepenia, nausea, vomiting, and diarrhoea were mild
and tolerable. Severe toxicity over grade 3 was not observed.
The response to CRT was CR in 21 patients (31%), PR in 31
(46%), and NC in 15 (22%). Recurrence was noted in 26 patients
(39%), including 11 with progressive disease. Of the patients who
achieved pCR, nine (42.8%) had recurrence. Three patients had
superficial local recurrence, and six had invasive local recurrence
or distant metastases. A total of 15 patients suffered cancer-related
death.
No statistical relation was found when treatment response (CR
or non-CR) was compared with tumour stage, grade CDDP doses,
or radiation doses (Table 4).
Deletion mapping of chromosome 1 and chromosome 17
Table 2 shows the prevalence of allelic imbalance and the fraction
of heterozygosity, which ranged between 0.68 and 0.96. Figure 1
summarises the results of allelic imbalance of the 14 microsatellite
markers. Not done was defined either as when DNA amplification
failed for technical reasons, or when the specific chromosomal
allele did not show heterozygosity with the control lymphocyte
DNA. Of the 67 tumours, allelic imbalance was observed from 21.1
to 56.1% in 14 markers. A significantly higher frequency of allelic
imbalance was observed in the p73 locus than those at the p53
locus (56.1 vs 21.1%, P¼0.003).
Relation of allelic imbalance to clinicopathological
parameters and treatment response
Table 3 shows the relationship of allelic imbalance to tumour stage
and grade. Except for the D1S507 locus, no statistically significant
association was found between allelic imbalance and tumour stage
or grade at any locus. At the D1S507 locus, allelic imbalances were
observed at a significantly high frequency in the progressive stage
(Po0.0305).
As for the relationship between allelic imbalance and treatment
response, significant differences of allelic imbalance were not
observed between CR and non-CR patients at each locus (Table 4).
Correlation between cause-specific survival and allelic
imbalance
Table 5 shows the correlation between cause-specific survival and
candidate-predictive factors including allelic imbalance at each
locus. Significant correlation was observed between allelic
imbalances of TP73 (imbalance: death 10 vs alive 22; balance:
death 0 vs alive 25, P¼0.0013) or its neighbour locus, D1S243
(imbalance: death 6 vs alive 12; balance: death 4 vs alive 34,
P¼0.0482) and survival rate; whereas no association was observed
at TP53 (imbalance: death 3 vs alive 9; balance: death 8 vs alive 37,
P¼0.4529). Clinical parameter, grade, stage treatment response;
CR or non-CR (imbalance: death 4 vs alive 17; balance: death 13 vs
alive 33, P¼04916), and CDDP dose did not correlate with cause-
specific survival, although significant correlation was observed
between survival rate and recurrence or no recurrence
(P¼0.0027), performance status (0.0113), and radiation doses
(P¼0.0486), respectively. By multivariate analysis before treat-
ment, an allelic imbalance of TP73 was the most useful
independent predictive factor in predicting cause-specific survival
in bladder cancer patients treated by CRT (Table 5, P¼0.0002,
Risk ratio: 3382). Figure 2 plots the Kaplan–Meier’s survival
curves stratified by treatment response, and allelic imbalance of
TP73, D1S243, and TP53.
Table 2 Prevalence of allelic imbalance, and observed heterozygosities
at different loci in lp and 17p
Allelic imbalance
Marker Locus No/Informative case (%)
Observed
heterozygosities
1 D1S171 Ip36.3 19/55 (34.5) 0.78
2 TP73 lp36.2–36.3 32/57 (56.1) 0.86
3 D1S243 lp36.2–36.3 18/57 (32.1) 0.86
4 D1S244 lp36.2–36.3 19/57 (32.8) 0.74
5 RIZ Ip36.2 22/56 (39.3) 0.68
6 D1S507 Ip36.1–36.2 20/57 (35.1) 0.83
7 D1S247 Ip35–36.1 24/57 (42.1) 0.81
8 ABR 17pl3.3 28/57 (49.1) 0.96
9 D17S1574 17pl3.3 15/56 (26.8) 0.68
10 YNZ22 17pl3.3 19/54 (35.2) 0.63
11 D17S1566 17pl3.2–13.3 12/57 (21.1) 0.72
12 ENO3 17pl3.2 18/55 (32.7) 0.89
13 TP53 17pl3.1 12/57 (21.1) 0.72
14 D17S520 17pl2–13.1 15/58 (25.9) 0.74
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Figure 1 Deletion mapping on chromosomes 17p13 (A) and 1p36 (B) in bladder cancer. Hetero, heterozygote; Homo, homozygote; AI, allelic
imbalance; RER, replication error.
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We applied a newly developed fluorescent multiplex-PCR techni-
que, which achieves superior resolution when compared with
isotopic methods, to microsatellite detection. We found loss of
heterozygosity (LOH) at many loci on chromosomes 1 and 17 in 67
bladder cancers. Previous studies have identified LOH at 3p, 4p,
4q, 6p, 8p, 9p, 9q, 10q, 11p, 13q, 14q, 17p, and 18q in advanced
bladder cancers (Tsai et al, 1990; Reznikoff et al, 1996). Close
association of LOH found at specific locations to prognosis as well
as chemotherapy response was reported in other malignancies
(Feugeas et al, 1996). Sengelov et al (2000) reportedly found no
predictive markers including LOH at 1p, 8p, 10p, 13q, and 17p for
response to chemotherapy in advanced bladder cancer. Their data
is in contrast with our data showing the close association of allelic
imbalance at p73 with cause-specific survival in patients who were
treated by CRT in bladder cancer, although the prevalence of allelic
imbalance at p73 did not correlate with treatment response. We
consider that their series analysed patients with more advanced
disease (metastatic or recurrent) and with resistant to various
treatments before chemotherapy; thus, having a much worse
prognosis than the group of patients in our study. Sengelov’s series
might have had more heterogeneous changes of genes than that of
our series. In our study, patients were only locally advanced
primary treated cases and not recurrent or metastatic cases.
Therefore, we believe that their series would not have shown a
significant correlation between allelic imbalances and response to
chemotherapy or duration of survival.
LOH at 17p is common, 40–63%, in patients with advanced
bladder cancer (Olumi et al, 1990; Tsai et al, 1990; Dalbagni et al,
1993; Reznikoff et al, 1996). Many tumours with LOH at the 17p
locus have been shown to have mutations in the retained 17p allele
(at the p53 locus) affecting mutated P53 protein overexpression.
p53 is one of the most important genes in the tumour suppressor
or regulator cell cycle and apoptosis. In addition, expression of p53
is induced by several types of DNA damage caused by CDDP or
irradiation. LOH at 17p (including the p53 locus) have been shown
to predict a poor response to chemotherapy in head and neck
cancer. In contrast to these data, our results are in good agreement
with another study showing a lack of relation between p53
mutation and chemotherapy response (Sengelov et al, 2000).
Another region of interest is on 17p13.3, telomeric to the TP53
locus in several types of tumours, where the presence of new
tumour suppressor genes is indicated in hepatocellular carcinoma,
malignant astrocytoma, paediatric primitive neuroectodermal
tumours, breast cancer, high grades of astrocytic tumours, and
ovarian cancer (Biegel et al, 1992; Saxena et al, 1992; Nishida et al,
1993; Isomura et al, 1994; Phillips et al, 1996; Chattopadhyay et al,
1997; Haataja et al, 1997). In lung cancer, new tumour suppressor
gene(s) may reside on three distinctly deleted regions on
chromosome 17p13.3 distal to the p53 gene, with possible roles
in progression and differentiation of adenocarcinomas (Tsuchiya
et al, 2000). Thus, we expected that new tumour suppressors or
apoptosis-related genes may reside in 17p13 regions and
investigated LOH of the TP53 locus and its distal regions.
However, we did not find any correlation between the prevalence
of LOH at each locus and tumour grade, stage, or response to CRT.
In our study, the prevalence of LOH at the TP53 locus was not very
frequent. These results suggest that LOH study at the p53 gene and
its neighbour locus is not important for predicting chemoradio-
sensitivity or survival in locally advanced bladder cancer.
However, loss of function of p53 by genetic or epigenetic changes
is a most important factor in the malignant potential of bladder
cancer, and further examination is needed to predict the clinical
course treated by CRT.
The distal region of the short arm of human chromosome 1
(1p36) is thought to contain tumour suppressor genes, such as
p73and RIZ, in a variety of cancers. The p73 gene, a member of p53
gene family, is also an important gene reflecting apoptosis or
tumorigenesis in bladder cancer. The p73 gene has been mapped at
chromosome 1p36.3, a region frequently deleted in breast cancer,
neuroblastoma, and other malignancies (Han et al, 1999; Ichimiya
et al, 1999; Ahomadegbe et al, 2000). RIZ, retinoblastoma protein
(Rb)-interacting zinc-finger gene (PRDM2), was isolated during
functional screening for Rb-binding proteins (Buyse et al, 1995)
and was mapped to 1p36.2; the RIZ locus is a target of frequent
deletion in hepatocellular carcinoma (Fang et al, 2000). Several
reports have suggested that p73 is not likely to be a tumour
suppressor gene, and that its overexpression by the activation of a
silent allele may contribute to the progression of bladder cancer
(Chi et al, 1999; Yokomizo et al, 1999). In contrast, Ono et al
(2001) demonstrated that the absence of CDDP-induced apoptosis
in p53-defective TCC cells, established CDDP-resistant sublines
from the TCC cell line T24, may be attributable to a loss of p73
induction that would be followed by insufficient caspase activa-
tion. Our results are partially consistent with their data, leading to
the hypothesis that inactivation of p73 may be the cause of
acquired resistance to CDDP observed in TCC in clinical settings.
Table 3 Correlation of grade and stage to frequency of allelic imbalance
Histological grade Clinical stage
G2/G3(%) P-value Tl1T2/T3 & T4 (%) P-value
1 D1S 171 9.1/25.5 0.4845 NS 3.6/14.6/16.4 0.6891 NS
2 TP73 13.0/44.4 0.5014 NS 12.3/15.8/28.1 0.1755 NS
3 D1S243 5.4/26.8 1.0000 NS 5.4/10.7/16.1 0.8545 NS
4 D1S244 5.4/26.8 0.7320 NS 5.4/8.9/17.9 0.6173 NS
5 RIZ 5.4/33.9 0.3287 NS 5.4/17.9/16.1 0.6118 NS
6 D1S507 7.0/28.1 1.0000 NS 0/17.5/17.5 0.0305
7 D1S247 8.8/33.3 1.0000 NS 7.0I10.5/24.6 0.2440 NS
8 ABR 12.3/36.8 0.6982 NS 8.8/14.0/26.3 0.4749 NS
9 D17S1574 7.1/19.6 0.7145 NS 3.6/10.7/12.5 0.8435 NS
10 YNZ22 7.4/25.9 1.0000 NS 3.7/11.1/18.5 0.5769 NS
11 D17S1566 5.3/15.8 1.0000 NS 1.8/8.8/10.5 0.5492 NS
12 ENO3 5.5/29.1 0.5114 NS 5.5/10.9/18.2 0.8332 NS
13 TP53 3.6/17.9 1.0000 NS 3.5/8.8/8.8 0.9198 NS
14 D17S520 7.0/17.5 0.2882 NS 3.5/8.6/13.8 0.7008 NS
NS¼not significant.
Table 4 Correlation of treatment response to frequency of allelic
imbalance and clinical parameters
Variable CR Non-CR P-value
Microsatellite markers 1 D1S171 7.3 27.3 (%) 0.1489 NS
2 TP73 16.7 40.7 0.6953 NS
3 D1S243 12.5 19.6 0.5895 NS
4 D1S244 8.9 23.2 0.7633 NS
5 RIZ 16.1 23.2 0.3748 NS
6 D1S507 12.3 22.8 0.9919 NS
7 D1S247 8.8 33.3 0.0878 NS
8 ABR 12.3 36.8 0.1897 NS
9 D17S1574 8.9 17.9 1.0000 NS
10 YNZ22 9.3 24.1 0.7635 NS
11 D17S1566 5.3 15.8 0.7338 NS
12 ENO3 9.1 25.5 0.5542 NS
13 TP53 8.9 12.5 0.5230 NS
14 D17S520 6.9 19.0 0.7515 NS
Clinical parameters
G2 or G3 31.3 68.7 (%) 0.7601 NS
TlorT2orT3&T4 31.3 68.7 0.3066 NS
CDDP dose
a 216 237 (mg) 0.2107 NS
Radiation dose
a 40.9 40.5 (Gv) 0.8665 NS
aMean dose. CR¼clinical response; CDDP¼cis-platinum; NS¼not significant.
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lIt is likely that p73 overexpression may occur during an early to
intermediate phase of bladder cancer. Cancer cells at that
time acquire a more malignant behaviour, and they could lose
one allele at many loci, including the p73 gene, due to genomic
instability at an advanced stage of bladder cancer. Indeed,
overexpression of p73 gene may be unnecessary for cancer cell
survival in a late phase.
In conclusion, our results suggest that the allelic imbalance at
p73 may be a useful prognostic indicator in bladder cancer patients
treated by CRT. This may enable appropriate candidates for CRT
Table 5 Univariate and multivariate analyses for predicting cause-specific survival in bladder cancer patients treated with chemoradiotherapy
(a) Univariate analysis
a (b) Multivariate analysis
b
Variable Category P-value Risk ratio (95% CI) P-value
D1S 171 Balance or imbalance 0.2588 NS NS
Microsatellite markers TP73 0.0013 3382(not calculated) 0.0002
D1S243 0.0482 NS
D1S244 0.8444 NS NS
RIZ 0.6178 NS NS
D1S507 0.2756 NS NS
D1S247 0.9640 NS NS
ABR 0.2051 NS NS
D17S1574 0.1859 NS NS
YNZ22 0.3886 NS NS
D17S1566 0.5149 NS NS
ENO3 0.7176 NS NS
TP53 0.4529 NS NS
D17S520 0.2632 NS NS
Clinical parameters Age p68 years or 468 years 0.6652 NS NS
PS 0 or 40 0.0113 2.911(1.31–12.38)0.0047
Tumour grade G2 or G3 1.0000 NS NS
Tumour stage Tl or T2 or T3 & T4 0.5989 NS NS
Recurrence Yes or No 0.0027 3.467(1.50–14.90)0.0017
Response CR or non-CR 0.4916 NS NS
CDDP doses p220mg or 4220mg 0.3634 NS NS
Radiation doses p32.4Gy or 432.4Gy 0.0486 1.655(1.007–2.935) 0.0468
aUsed Log-rank test.
bUsed the Cox proportional hazard test. CDDP¼cis-platinum; CR¼clinical response; NS¼not significant.
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Figure 2 Kaplan–Meier survival curves stratified by TP53 (A), TP73 (B), D1S243 (C), and treatment response (D).
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lto be selected from among patients with locally advanced bladder
cancer. Patients with an allelic imbalance at p73 may be considered
for immediate cystectomy, rather than for bladder preservation by
CRT. Investigation of a larger number of patients with additional
follow-up treatment by CRT is required to validate our preliminary
results.
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